Critical Shortage of Chemotherapy Drugs Raises Alarm Among Oncologists in India
Concerns Over Chemotherapy Drug Shortage
Oncologists throughout India are expressing serious concerns regarding a significant shortage of two essential chemotherapy medications, Cisplatin and Carboplatin. They warn that this disruption in supply could severely impact treatment options for patients battling various common cancers. Experts have shared insights into the reasons behind this shortage and its implications for cancer patients.
Dr. Shyam Agarwal, a Senior Consultant in Medical Oncology at Sir Ganga Ram Hospital in New Delhi, reported that the hospital has been experiencing a lack of these vital drugs for nearly a month. He stated, "Cisplatin and Carboplatin are crucial for cancer treatment, and we have been facing shortages for the last 15 days to almost a month now." These platinum-based drugs are fundamental in treating prevalent cancers such as oral, breast, ovarian, cervical, esophageal, and testicular cancers. Dr. Agarwal emphasized their importance, saying, "These are essential drugs for saving the lives of these patients."
These medications are utilized in both early and advanced stages of cancer and are frequently combined with other anti-cancer therapies. Currently, Sir Ganga Ram Hospital has no Carboplatin in stock and only a few days' supply of Cisplatin remaining. Patients are also struggling to find these drugs in the market.
Dr. Agarwal explained that Carboplatin is available in two dosages, 150 mg and 450 mg, depending on the patient's needs and cancer stage. However, the 150 mg version has been unavailable for two to three weeks, forcing doctors to use larger vials and resulting in significant wastage of the medication. This shortage is reportedly widespread across India, affecting even VIP patients in cities like Bengaluru, Haryana, and Kerala.
Reasons Behind the Drug Shortage
Dr. Agarwal attributes the shortage to rising manufacturing costs and price controls imposed by the Drug Price Control Order (DPCO). He explained, "The production costs have surged due to the increased price of active pharmaceutical ingredients (APIs) imported from abroad. Consequently, manufacturing expenses have risen, but the maximum retail price has not changed." Cisplatin and Carboplatin are generic drugs produced by around 50 companies in India, including major manufacturers. Typically, these drugs cost patients between Rs 3,000-4,000 monthly. Dr. Agarwal noted that companies are struggling to maintain production levels due to these increased costs and have approached the government for a price revision. Some manufacturers have reportedly ceased production due to losses.
No Universal Replacement Available
Dr. Mandeep Singh Malhotra, Director of Surgical Oncology at CK Birla Hospital in Delhi, highlighted the seriousness of the situation for the oncology community. He stated, "The shortage of Cisplatin and Carboplatin is a significant concern. These drugs are foundational therapies that have been utilized for decades and are crucial in treating various common cancers." A large portion of chemotherapy protocols for solid tumors depends on these platinum-based agents, making their availability vital for timely cancer treatment. Dr. Malhotra emphasized that there is currently no direct substitute for these drugs across all cancer types. He urged that maintaining a steady supply is essential to avoid treatment disruptions and protect patient outcomes. Dr. Agarwal echoed this sentiment, stating, "We need these medicines. Patients are suffering," and called for government intervention to ensure the production of these affordable drugs.